Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: A comparative analysis

International Journal of Clinical Oncology

Volumn 16, Issue 2, 2011, Pages 125-132

  Chua, Terence C ^a   Saxena, Akshat ^a   Chu, Francis ^a   Butler, S Patrick ^a   Quinn, Richard J ^a   Glenn, Derek ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Hepatectomy; Hepatocellular carcinoma; Iodine 131; Lipiodol; Liver resection

Indexed keywords

IODINE 131;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE-FREE SURVIVAL; ETHIODIZED OIL; FEMALE; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79959828492     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-010-0143-9     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
2. Lavanchy D (2009) The global burden of hepatitis C. Liver Int 29 Suppl 1:74-81
3. Lavanchy D (2005) Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 34 suppl 1:S1-S3
4. Llovet JM, Bruix J (2000) Early diagnosis and treatment of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 14:991-1008 (Pubitemid 32094270)
5. Poon RT, Fan ST, Lo CM et al (2004) Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg 240:698-708 (discussion 708-710)
6. Yoo HY, Patt CH, Geschwind J-F et al (2003) The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 21:4329-4335 (Pubitemid 46621808)
7. Poon RT, Fan ST, Lo CM et al (2007) Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg 245:51-58 (Pubitemid 46035435)
8. Katz SC, Shia J, Liau KH (2009) Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg 249:617-623
9. Nathan H, Schulick RD, Choti MA et al (2009) Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 249:799-805
10. Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48:S20-S37
11. Raoul JL, Boucher E, Roland V et al (2009) 131-Iodine lipiodol therapy in hepatocellular carcinoma. Q J Nucl Med Mol Imaging 53:348-355
12. Lau WY, Leung TW, Ho SK et al (1999) Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353:797-801 (see comment)
13. Ng KM, Niu R, Yan TD et al (2008) Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma. HPB (Oxf) 10:388-395
14. Madsen MT, Park CH, Thakur ML (1988) Dosimetry of iodine-131 ethiodol in the treatment of hepatoma. J Nucl Med 29:1038-1044
15. Lau WY, Lai EC, Leung TW et al (2008) Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 247:43-48
16. Pocock S, White I (1999) Trials stopped early: too good to be true? Lancet 9157:943-944
17. Boucher E, Corbinais S, Rolland Y et al (2003) Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 38:1237-1241 (see comment)
18. Tabone M, Vigano L, Ferrero A et al (2007) Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. Eur J Surg Oncol 33:61-66 (Pubitemid 46131882)
19. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390 (see comment)